An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: Insights, limitations and future directions

Jul 27, 2025Progress in neuro-psychopharmacology & biological psychiatry

How psilocybin, LSD, MDMA, and ketamine may renew psychedelic-assisted therapy: key insights, challenges, and future possibilities

AI simplified

Psychedelic Science on OpenScience ↗PubMed ↗DOI ↗

Abstract

Psychedelic compounds like psilocybin, LSD, MDMA, and ketamine are increasingly recognized for their therapeutic potential in treating complex mental health conditions.

Psychedelics may work by modulating serotonin receptors and altering brain connectivity.
Each psychedelic has a unique pharmacological profile and specific clinical applications.
Psilocybin and LSD engage similar serotonergic pathways but differ in how they affect receptors and subjective experiences.
MDMA is associated with empathogenic properties, while ketamine may provide rapid antidepressant effects.
Recent FDA designations for psilocybin and MDMA indicate a shift towards acceptance based on evidence.
The field faces challenges including methodological limitations, regulatory hurdles, and ethical considerations.

AI simplified

The resurgence of psychedelic-assisted psychotherapy marks a pivotal evolution in mental health treatment, challenging traditional paradigms by integrating compounds such as psilocybin, LSD, MDMA, and ketamine into clinical practice. Historically marginalized due to regulatory and societal concerns, these agents are now gaining recognition for their unique neurobiological mechanisms and therapeutic potential in addressing complex conditions like depression, PTSD, and addiction. Unlike conventional treatments, psychedelics exert their effects primarily through modulation of serotonin receptors and brain network connectivity, with each substance demonstrating distinct pharmacological profiles and clinical applications. Notably, psilocybin and LSD share serotonergic pathways but differ in receptor specificity and subjective effects, while MDMA's empathogenic properties and ketamine's rapid antidepressant action offer alternative therapeutic avenues. Recent FDA breakthrough therapy designations for psilocybin and MDMA underscore a shift toward evidence-based acceptance, yet the field remains challenged by methodological limitations, regulatory barriers, and ethical considerations. This narrative review synthesizes historical developments, mechanistic insights, and clinical outcomes, emphasizing the need for rigorous research, diverse patient cohorts, and thoughtful integration of psychedelics with psychotherapeutic modalities to realize their full therapeutic promise.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: Insights, limitations and future directions

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the psychedelic science brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the psychedelic science brief